These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27537201)

  • 1. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).
    Oliveira EF; Santos-Martins D; Ribeiro AM; Brás NF; Cerqueira NS; Sousa SF; Ramos MJ; Fernandes PA
    Expert Opin Ther Pat; 2016 Nov; 26(11):1257-1272. PubMed ID: 27537201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
    Pfefferkorn JA
    Expert Opin Ther Pat; 2011 Feb; 21(2):187-203. PubMed ID: 21214503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
    Davidson MH
    Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
    Pfefferkorn JA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE
    Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
    Essig M; Vrtovsnik F; Friedlander G
    Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
    da Silva VB; Taft CA; Silva CH
    J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of statin therapy on the progression of chronic kidney disease.
    Shah S; Paparello J; Danesh FR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG CoA reductase inhibitors.
    Feussner G
    Curr Opin Lipidol; 1994 Feb; 5(1):59-68. PubMed ID: 15559032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
    Pallottini V
    Expert Opin Ther Pat; 2015; 25(10):1079-83. PubMed ID: 26135220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
    Baskaran G; Salvamani S; Ahmad SA; Shaharuddin NA; Pattiram PD; Shukor MY
    Drug Des Devel Ther; 2015; 9():509-17. PubMed ID: 25609924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia.
    Gesto DS; Pereira CMS; Cerqueira NMFS; Sousa SF
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32859023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.
    Chong PH
    Ann Pharmacother; 2002 Dec; 36(12):1907-17. PubMed ID: 12452755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of statins in children.
    Lamaida N; Capuano E; Pinto L; Capuano E; Capuano R; Capuano V
    Acta Paediatr; 2013 Sep; 102(9):857-62. PubMed ID: 23631461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of statins.
    Sirtori CR
    Pharmacol Res; 2014 Oct; 88():3-11. PubMed ID: 24657242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A general assessment of the safety of HMG CoA reductase inhibitors (statins).
    Black DM
    Curr Atheroscler Rep; 2002 Jan; 4(1):34-41. PubMed ID: 11772420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.